|
Oct 9
|
Kintara Therapeutics Reveals Improved Financials, Merger Plans
|
|
Oct 8
|
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
|
|
Jul 8
|
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
|